Ayvakit FDA Approval History
FDA Approved: Yes (First approved January 9, 2020)
Brand name: Ayvakit
Generic name: avapritinib
Dosage form: Tablets
Company: Blueprint Medicines Corporation
Treatment for: Gastrointestinal Stromal Tumor
Ayvakit (avapritinib) is a kinase inhibitor for the treatment of PDGFRα exon 18 mutant gastrointestinal stromal tumors (GIST).
- Ayvakit is a tablet taken once daily on an empty stomach.
- Ayvakit can cause serious side effects including bleeding inside the skull, effects on the central nervous system, and harm to a newborn baby. Common side effects of include swelling, nausea, tiredness, trouble thinking, vomiting, decreased appetite, diarrhea, hair color change, increased tear secretion, abdominal pain, constipation, rash and dizziness.
Development Timeline for Ayvakit
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.